When was Moderna founded?

Moderna was founded in 2010 and raised its 1st funding round 2 years after it was founded.

Where is Moderna located?

Moderna is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Moderna have?

As of Aug 31, 2026, the latest employee count at Moderna is 6231.

Is Moderna a funded company?

Moderna is a funded company, having raised a total of $2.78B across 22 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 27, 2012.

When was the latest funding round of Moderna?

Moderna's latest funding was a $***** Grant (prize money) round on Jan 17, 2025, with participation from 1 investor.

What is the annual revenue of Moderna?

Annual revenue of Moderna is more than $1B as on Dec 31, 2025

Where does Moderna rank among its competitors?

Moderna ranks 6th amongst 2733 active competitors, of which 907 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Moderna?

Moderna's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Moderna - 2026 Company Profile, Team, Funding, Competitors & Financials

Moderna is a public company based in Cambridge (United States), founded in 2010 by Timothy A Springer, Robert S Langer, Derrick Rossi and Kenneth R Chien. It operates as a Developer of mRNA-based therapeutics for a wide range of diseases. Moderna has raised $2.78B in funding from investors like Merck, AstraZeneca and HHS. The company has 2733 active competitors, including 907 funded and 666 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of mRNA-based therapeutics for a wide range of diseases. The company produces human proteins, antibodies, or vaccines inside patient cells, which are in turn active intracellularly or secreted. The company is also developing vaccines in different disease areas such as infectious diseases, cancer, rare diseases, and COVID-19.

Website: www.modernatx.com/en-US
Social
Email ID: *****@modernatx.com
Phone Number: +1 **********
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2010

Location

Cambridge, United States

Stage

Public

Total Funding

$2.78B in 22 rounds

Latest Funding Round

Grant (prize money), Jan 17, 2025, $*****

Investors

Merck & 33 more

Ranked

6^th among 2733 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

6,231 as on Aug 31, 2026

Investment & Acquisitions

OriCiro Genomics & 1 more

Similar Companies

Strand Therapeutics & 421 more

Exit Details

Public

View Moderna's full profile

Moderna is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Modernatx, Inc. CIN: 204977193 , United States, Active	Dec 07, 2022	-	-	-
MODERNA, INC. CIN: 1682852 , United States, Active		$1B+ (As on Dec 31, 2025)	-	-
Moderna Therapeutics Inc. CIN: 270226313 , United States, Active	Dec 31, 1999	-	4822 (As on Dec 31, 2024)	-

Moderna got listed on Dec 07, 2018.

Click here to take a look at Moderna's IPO in detail

Moderna has raised a total funding of $2.78B over 22 rounds. Its first funding round was on Nov 27, 2012. Its latest funding round was a Grant (prize money) round on Jan 17, 2025 for $*****. 1 investor participated in its latest round. Moderna has 34 institutional investors.

Here is the list of recent funding rounds of Moderna:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 17, 2025	1839469	Grant (prize money)	4540704	5068526	4359274	5331516
Jul 02, 2024	5228248	Grant (prize money)	2908902	8947442	3830172	1138917
Oct 08, 2020	8400134	Grant (prize money)	2751245	6458199	3822874	DARPA

Access funding benchmarks and valuations. Sign up today!

View details of Moderna's funding rounds and investors

The founders of Moderna are Timothy A Springer, Robert S Langer, Derrick Rossi and Kenneth R Chien.

Here are the details of Moderna's key team members:

Timothy A Springer: Co-Founder of Moderna. They are also an angel investor in 2 startups.
Contact Info: 1 email address
Robert S Langer: Co-Founder of Moderna.
Derrick Rossi: Co-Founder of Moderna.
Contact Info: 1 email address
Kenneth R Chien: Co-Founder of Moderna.

View details of Moderna's Founder profiles and Board Members

Moderna's employee count trend

Moderna has 6,231 employees as of Aug 26. Here is Moderna's employee count trend over the years:

Uncover Moderna's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Moderna include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Moderna, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	ADS Ventures, Alcor Fund & 32 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100